Articles
Latest Articles
Evidence-based analysis and clinical commentary on peptide therapeutics — updated as the literature evolves. · 14 articles
Why Do GIP Receptor Agonists and Antagonists Both Produce Weight Loss in 2026 Obesity Trials?
Both GIP receptor (GIPR) agonism and antagonism reduce body weight in preclinical and early clinical models, a paradox explained by tissue-specific receptor desensitisation, differential central versus peripheral signalling, and the obligate co-presence of GLP-1 receptor activity in every trial where antagonism has shown efficacy. Neither pharmacological direction acts on GIPR in isolation.
Do GLP-1 Receptor Agonists Increase the Risk of Clinically Recorded Hair Loss Compared With Other Diabetes Drug Classes in 2026?
A 2024 BMJ target-trial emulation using Penn Medicine electronic health records found that GLP-1 receptor agonist initiators had a statistically significant higher incidence of clinically recorded alopecia than users of DPP-4 inhibitors or SGLT-2 inhibitors, with an adjusted hazard ratio of approximately 1.33 versus DPP-4 inhibitors after propensity-score weighting.